Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Other Non-Current Liabilities (2020 - 2025)

Rapid Micro Biosystems (RPID) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $186000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 37.58% to $186000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $186000.0 through Dec 2025, down 37.58% year-over-year, with the annual reading at $186000.0 for FY2025, 37.58% down from the prior year.
  • Other Non-Current Liabilities hit $186000.0 in Q4 2025 for Rapid Micro Biosystems, down from $358000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $15.6 million in Q2 2021 to a low of $186000.0 in Q4 2025.
  • Historically, Other Non-Current Liabilities has averaged $1.9 million across 5 years, with a median of $293500.0 in 2024.
  • Biggest five-year swings in Other Non-Current Liabilities: skyrocketed 345.84% in 2021 and later tumbled 95.53% in 2022.
  • Year by year, Other Non-Current Liabilities stood at $1.2 million in 2021, then crashed by 81.07% to $229000.0 in 2022, then grew by 14.85% to $263000.0 in 2023, then grew by 13.31% to $298000.0 in 2024, then crashed by 37.58% to $186000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for RPID at $186000.0 in Q4 2025, $358000.0 in Q3 2025, and $314000.0 in Q2 2025.